<DOC>
	<DOCNO>NCT03069352</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , placebo-controlled , multicenter study assess efficacy safety venetoclax co-administered low dose cytarabine ( LDAC ) versus LDAC co-administered placebo treatment naïve participant acute myeloid leukemia ( AML ) ineligible intensive induction chemotherapy .</brief_summary>
	<brief_title>A Study Venetoclax Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible Intensive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Participants must histological confirmation Acute Myeloid Leukemia ( AML ) World Health Organization ( WHO ) criterion , ineligible intensive induction chemotherapy . Participants must adequate renal liver function . Participant receive prior treatment AML exception hydroxyurea , allow first cycle study treatment . Participant antecedent myeloproliferative neoplasm ( MPN ) include myelofibrosis , essential thrombocytosis , polycythemia vera , chronic myelogenous leukemia ( CML ) without BCRABL mutation . Participant acute promyelocytic leukemia ( APL ) . Participant known central nervous system ( CNS ) involvement AML . Participant known Human Immunodeficiency Virus ( HIV ) infection , know positive hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>Venetoclax</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Cytarabine</keyword>
</DOC>